Placebo News and Research

RSS

Study shows risk of Guillain-Barre syndrome after vaccination is extremely low

Patients are not at increased risk of Guillain-Barr- syndrome in the six-week period after vaccination with any vaccine, including influenza, according to a Kaiser Permanente study published in Clinical Infectious Diseases.

25 Jun 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx Therapeutics announced today that clinical study results confirm that the primary site of action of Type 2 diabetes medicine metformin is in the lower bowel rather than in the circulation.

24 Jun 2013

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada.

24 Jun 2013

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.

24 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

One of the largest clinical trials done in infants with congenital (present at birth) heart diseases, published in the New England Journal of Medicine, shows that the increasingly common practice of using the drug clopidogrel (Plavix-) to reduce shunt-related blood flow issues is not effective in the dose studied.

21 Jun 2013

Laughing gas is associated with increased risk for perioperative cardiac events

A clinical trial published in the July issue of Anesthesiology may shed some light on whether nitrous oxide ("laughing gas") causes an increased risk for cardiac events, including heart attacks after surgery, particularly among high-risk patients.

20 Jun 2013

Researchers launch clinical trial on stem cells to prevent amputations in end stage PAD

University Hospitals Case Medical Center clinical researchers have launched an innovative clinical trial, unique in its design, which will evaluate the ability of a patient's own stem cells to prevent leg amputations in end stage peripheral arterial disease (PAD).

20 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

Loyola researcher to study role of Vitamin D in women with diabetes and depression

A Loyola University Chicago Niehoff School of Nursing researcher has received a four-year, $1.49 million grant to study whether Vitamin D can improve mood in women with diabetes who are depressed.

20 Jun 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

Estrogen replacement therapy reduces anxiety symptoms in girls with anorexia nervosa

Estrogen replacement therapy is associated with a significant decrease in anxiety symptoms among girls with anorexia nervosa, a new clinical trial finds. The results will be presented today at The Endocrine Society's Annual Meeting in San Francisco.

18 Jun 2013

TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

TWi Biotechnology, Inc. announced that it has completed the patient enrollment in a phase II trial of AC-201 for Gout Flare Prophylaxis during urate-lowering therapy. This randomized, double-blind, placebo-controlled Phase II study is conducted in 8 major medical centers in Taiwan.

18 Jun 2013

Placebo News and Research

Study shows risk of Guillain-Barre syndrome after vaccination is extremely low

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

Laughing gas is associated with increased risk for perioperative cardiac events

Researchers launch clinical trial on stem cells to prevent amputations in end stage PAD

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Loyola researcher to study role of Vitamin D in women with diabetes and depression

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Estrogen replacement therapy reduces anxiety symptoms in girls with anorexia nervosa

TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

Vanda presents additional data from tasimelteon Phase III studies at ENDO 2013

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Vaccine given to newborns 60% effective against rotavirus in Ghana

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News